Montelukast for Prevention & Treatment of OHSS

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

montelukast & dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Benha University
• Collaborator: Hawaa Fertility Center
• Treatments: Montelukast; Progesterone

Criteria

Inclusion Criteria:

• PCOS high responders high numbers of ovum retrieved

Exclusion Criteria:

• hypersensitivity to any drug components phenylketonuria patients depression liver dysfunction